{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:22:03Z","timestamp":1793251323498,"version":"4.5.0"},"reference-count":22,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s443177","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T01:05:06Z","timestamp":1712711106000},"page":"1143-1151","source":"Crossref","is-referenced-by-count":28,"title":["The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov"],"prefix":"10.2147","volume":"Volume 18","author":[{"given":"Sarah","family":"Norring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spigarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1055\/s-0028-1097672","volume":"29","author":"Schultes","year":"1976","journal-title":"Planta Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.1979.10472087","volume":"11","author":"Schultes","year":"1979","journal-title":"J Psychedelic Drugs"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02159243","volume":"14","author":"Hofmann","year":"1958","journal-title":"Experientia"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02160424","volume":"14","author":"Hofmann","year":"1958","journal-title":"Experientia"},{"key":"ref5","unstructured":"DEA. Drug Scheduling. Available from: https:\/\/www.dea.gov\/drug-information\/drug-scheduling. Accessed June 1, 2023."},{"key":"ref6","unstructured":"Research and Markets. Psychedelic drugs market, global forecast. Available from: https:\/\/www.researchandmarkets.com\/reports\/5240207\/psychedelic-drugs-market-by-drugs-lsd?utm_source=GNOM&utm_medium=PressRelease&utm_code=894w6r&utm_campaign=1513085+-+Global+Psychedelic+Drugs+Market+Report+2020%3a+Market+Size+is+Projected+to+Reach+%2410.75+Billion+by+2027&utm_exec=chdo54prd. Accessed June 1, 2023."},{"key":"ref7","unstructured":"ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/. Accessed December 12, 2023."},{"key":"ref8","unstructured":"FDA. Development and approval process. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs. Accessed June 1, 2023."},{"key":"ref9","unstructured":"FDA. Breakthrough therapy. Available from: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/breakthrough-therapy. Accessed June 1, 2023."},{"key":"ref10","unstructured":"Compass Pathways. COMPASS pathways receives FDA breakthrough therapy designation. Available from: https:\/\/compasspathways.com\/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression\/. Accessed June 1, 2023."},{"key":"ref11","unstructured":"Business Wire. FDA grants breakthrough therapy designation. Available from: https:\/\/www.businesswire.com\/news\/home\/20191122005452\/en\/FDA-grants-Breakthrough-Therapy-Designation-to-Usona-Institutes-psilocybin-program-for-major-depressive-disorder. Accessed June 1, 2023."},{"key":"ref12","unstructured":"Pharma News Intelligence. Understanding US food and drug administration (FDA) approval processes. https:\/\/pharmanewsintel.com\/features\/understanding-us-food-and-drug-administration-fda-approval-processes. Accessed June 1, 2023."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/molecules26102948","volume":"26","author":"Lowe","year":"2021","journal-title":"Molecules"},{"key":"ref14","unstructured":"Biotechnology Innovation Organization. Clinical development success rates and contributing factors 2011\u20132020. https:\/\/go.bio.org\/rs\/490-EHZ-999\/images\/ClinicalDevelopmentSuccessRates2011_2020.pdf. Accessed June 1, 2023."},{"key":"ref15","unstructured":"FDA. Step 3 clinical research. Available from: https:\/\/www.fda.gov\/patients\/drug-development-process\/step-3-clinical-research#:~:text=Study%20Participants%3A%2020%20to%20100,people%20with%20the%20disease%2Fcondition.&text=During%20Phase%201%20studies%2C%20researchers,condition%20participate%20in%20Phase%201. Accessed June 1, 2023."},{"key":"ref16","unstructured":"FDA. Fast Track. Available from: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/fast-track. Accessed June 1, 2023."},{"key":"ref17","unstructured":"FDA. Psychedelic drugs: considerations for clinical investigations. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investigations. Accessed December 12, 2023."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"ref19","unstructured":"NAMI. Mental health by the numbers. Available from: https:\/\/www.nami.org\/mhstats. Accessed June 1, 2023."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"ref21","unstructured":"NIH. CinicalTrials.gov glossary terms. Available from: https:\/\/clinicaltrials.gov\/ct2\/about-studies\/glossary. Accessed June 1, 2023."},{"key":"ref22","unstructured":"Definitive Healthcare. How to recruit patients for clinical trials in 3 steps. Available from: https:\/\/www.definitivehc.com\/blog\/recruit-patients-for-clinical-trials#:~:text=Finding%20people%20willing%20to%20participate,in%20the%20clinical%20trial%20market. Accessed June 1, 2023."}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=98235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=98235","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T01:05:16Z","timestamp":1712711116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/the-promise-of-therapeutic-psilocybin-an-evaluation-of-the-134-clinica-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":22,"URL":"https:\/\/doi.org\/10.2147\/dddt.s443177","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}